Bometase Alfa
Preclinical
Bometase Alfa is one of 3 therapeutic programs targeting Acquired Hemophilia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Acquired Hemophilia
#DrugCompanyPhaseTrials
1Hemlibra
RochePhase 2
OBIZUR
TakedaPreclinical
Bometase Alfa
IInstitute of Hematology & Blood Diseases Hospital, China
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acquired Hemophilia1 trial
Efficacy and Safety of Bometase Alfa for the Treatment of Bleeding in Acquired Hemophilia A: A Prospective, Single-Arm, Exploratory Study
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07789587·20 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Bometase Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]